Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
13
2020
Cures Act Developments: FDA Publishes CFR Amendments Exempting Class II Devices with an Interesting Addition Mintz
Feb
10
2016
Deciphering Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers Mintz
Mar
15
2016
Tackling Drug Prices: CMS and PhRMA Propose Steps to Promote Value-Based Purchasing Mintz
Mar
17
2016
Fraudulent Dietary Supplements Highlighted in 2016 National Consumer Protection Week Mintz
Apr
1
2016
Biosimilar Developments Continue at a Rapid Pace Mintz
Jul
25
2023
First Nonprescription Birth Control Pill Approved for Marketing by FDA: A Milestone for Reproductive Health Mintz
May
5
2016
NYC Extends Tax Credit Available to Biotech Companies Mintz
Jul
18
2016
House Passes GE Labeling Bill; Obama Expected to Sign Mintz
Apr
22
2020
FDA Continues Its Diverse Agency Actions in Response to COVID-19 Pandemic Mintz
Aug
31
2016
6-Month Notice from a Biosimilar Sponsor Always Required — Says Federal Circuit Mintz
Nov
20
2023
The LDT Debate: Unpacking Public Responses to FDA’s Proposed Rule Mintz
Jan
12
2017
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress Mintz
Jan
17
2017
FDA’s Enforcement Priorities Likely to Change in 2017 and Other “Unknowable Knowns” Mintz
Mar
12
2024
FDA Needs a New Approach to AI/ML-Enabled Medical Devices Mintz
Sep
1
2020
Bioethics in a Pandemic: Learning from the Past Mintz
Sep
15
2020
Trump Signs Executive Orders Aimed at Tying Domestic Drug Prices to Foreign Prices Mintz
Mar
16
2017
21st Century Cures Act Developments: FDA Proposes Class II Device Exemptions Mintz
Jun
29
2017
Massachusetts House and Senate Tackle Marijuana Mintz
Aug
9
2017
Reading the Tea Leaves: Sales of Macadamia Nut Could Be Going Up! Mintz
Oct
10
2017
OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress Mintz
Mar
4
2012
Energy & Clean Tech Connections - Recent Washington D.C. Updates Mintz
May
21
2012
Energy and Environmental Law Update - May 20, 2012 Mintz
Aug
20
2012
Energy and Environment Law Update August 20, 2012 Mintz
Feb
1
2018
A Guide to New Jersey’s New Limits on Pharmaceutical Industry Payments to Prescribers Mintz
Apr
6
2013
Predictions of Single-Issue Energy Legislation, Hydraulic Fracturing, and American Energy Independence Mintz
May
27
2021
Pharmaceutical and Medical Device Manufacturers Be Advised: Sunshine Act / Open Payments Enforcement is on the Rise Mintz
Apr
13
2018
Report Details Uneven Implementation of the New Drug Tracing Law Mintz
Jul
3
2013
Energy and Environmental Law Update - Week of July 1, 2013 Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins